Established in 2027 in Kashiwa-no-ha Smart City, Mitsui Link Lab Kashiwa-no-ha 2, Asia's first development and manufacturing base for regenerative medicine products. In addition, we will contribute significantly to the development of cancer medicine in Japan and solve the problem of drug loss and drag lag

(Headquarters: Minato-ku, Tokyo; President & CEO: Omar Kurdi) and Mitsui Fudosan Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshi Ueda; hereinafter "Mitsui Fudosan") are pleased to announce that they will establish their headquarters and Asia development and manufacturing base for regenerative medicine products at Mitsui Link Lab Kashiwa-no-ha 2 (Headquarters: Minato-ku, Tokyo; President & CEO: Toshi Ueda; hereinafter "Mitsui Fudosan"), which is under construction at Kashiwanoha Smart City.

For more information, please refer to this press release.